TABLE OF CONTENTS

1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKETS COVERED 14
1.3 STAKEHOLDERS 15
1.4 MARKET SCOPE 15

2 RESEARCH METHODOLOGY 17
2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET CRACKDOWN & DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 KEY INDUSTRY INSIGHTS 22
2.3.4 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 27
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN GLOBAL HUMAN MICROBIOME MARKET 27
4.2 HUMAN MICROBIOME MARKET SNAPSHOT 28
4.3 NORTH AMERIA WILL BE THE FASTEST GROWING MARKET IN THE FORECAST PERIOD 29
4.4 HUMAN MICROBIOME MARKET: BY DISEASES 29
4.5 HUMAN MICROBIOME MARKET: BY PRODUCT 30
4.6 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 30
4.7 HUMAN MICROBIOME MARKET: BY APPLICATION 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 33
5.1.1 HUMAN MICROBIOME MARKET, BY APPLICATION 33
5.1.2 HUMAN MICROBIOME MARKET, BY DISEASE 34
5.1.3 HUMAN MICROBIOME MARKET, BY PRODUCT 34
5.2 MARKET DYNAMICS 35
5.2.1 DRIVERS 36
5.2.1.1 Human microbiome therapy, an emerging market 36
5.2.1.2 Human microbiome represents as new validated targets for drug development 37
5.2.1.3 Need for early disease detection and diagnosis driving the use of microbiomes in molecular diagnostics 37
5.2.2 RESTRAINTS 38
5.2.2.1 Lack of proper detailed research 38
5.2.2.2 Barriers to prove causal link between dysbiosis and disease 38
5.2.3 OPPORTUNITIES 39
5.2.3.1 IND requirements for fecal microbiota may boost market growth 39
5.2.3.2 Joint ventures, collaborations, & partnerships between companies 39
5.2.4 THREATS 40
5.2.4.1 Government regulations 40
5.2.5 BURNING ISSUES 41
5.2.5.1 Abundant opportunities in the microbiome field and tremendous research investments may boost the market 41
5.2.5.2 Various microbiome therapeutic products in various stages of development 42

6 INDUSTRY TRENDS 43
6.1 INTRODUCTION 43
6.2 INDUSTRY TRENDS 43
6.3 PORTER’S FIVE FORCES ANALYSIS 44
6.3.1 THREAT FROM NEW ENTRANTS 44
6.3.2 THREAT FROM SUBSTITUTES 45
6.3.3 BARGAINING POWER OF SUPPLIERS 45
6.3.4 BARGAINING POWER OF BUYERS 45
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 46
6.4 PEST ANALYSIS 46
6.4.1 POLITICAL FACTORS 46
6.4.2 ECONOMIC FACTORS 46
6.4.3 SOCIAL FACTORS 47
6.4.4 TECHNOLOGICAL FACTORS 47
6.5 STRATEGIC BENCHMARKING 47
6.5.1 RESEARCH AND TECHNOLOGY INTEGRATION & PRODUCT DEVELOPMENT 47
6.5.2 ENTRY INTO THE CHRONIC LIFESTYLE DISEASES MARKET 48

7 HUMAN MICROBIOME MARKET, BY DISEASE 50
7.1 INTRODUCTION 51
7.2 DIABETES 53
7.3 OBESITY 54
7.4 AUTOIMMUNE DISORDERS 56
7.5 CANCER 57
7.6 ACUTE DIARRHEA 59
7.7 MENTAL DISORDERS 60
7.8 OTHER DISEASES 63
 
8 HUMAN MICROBIOME MARKET, BY APPLICATION 65
8.1 INTRODUCTION 66
8.2 THERAPEUTICS 68
8.3 DIAGNOSTICS 70

9 MARKET, BY PRODUCT 72
9.1 INTRODUCTION 73
9.2 PROBIOTICS 75
9.3 PREBIOTICS 77
9.4 FOODS 78
9.5 MEDICAL FOOD 80
9.6 OTHER PROBIOTIC SUPPLEMENTS 81
9.7 DEVICES 83
9.8 DRUGS 84

10 GEOGRAPHIC ANALYSIS 86
10.1 INTRODUCTION 87
10.2 NORTH AMERICA 88
10.3 EUROPE 90
10.4 ASIA-PACIFIC 92
10.5 REST OF THE WORLD (ROW) 95

11 COMPETITIVE LANDSCAPE 97
11.1 OVERVIEW 97
11.2 NEW PRODUCT LAUNCHES 99
11.3 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS 99
11.4 EXPANSIONS 102
11.5 CLINICAL /RESEARCH STUDIES 102
11.6 PATENT FILLINGS AND APPROVALS 103
11.7 OTHER DEVELOPMENTS 105

12 COMPANY PROFILES 107
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 INTRODUCTION 107
12.2 ENTEROME BIOSCIENCE 108
12.3 SECOND GENOME, INC. 111
12.4 MICROBIOME THERAPEUTICS LLC. 114
12.5 VEDANTA BIOSCIENCES, INC. 117
12.6 METABIOMICS CORPORATION 119
12.7 E.I. DU PONT DE NEMOURS AND COMPANY 122
12.8 MERCK & CO., INC. 126
12.9 YAKULT HONSHA CO., LTD. 128
12.10 OSEL, INC. 131
12.11 VITHERA PHARMACEUTICALS 133
12.12 GT BIOLOGICS LTD. 136
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13 APPENDIX 139
13.1 INSIGHTS OF INDUSTRY EXPERTS 139
13.2 DISCUSSION GUIDE 140
13.3 INTRODUCING RT: REAL TIME MARKET INTELLIGENCE 143
13.4 AVAILABLE CUSTOMIZATIONS 144
1.1. RELATED REPORTS 145

LIST OF TABLES

TABLE 1 EARLY DISEASE DETECTION AND DIAGNOSIS IS A KEY DRIVER TO THE GROWTH OF THE MARKET 38
TABLE 2 LACK OF PROPER DETAILED RESEARCH CURBS THE MARKET GROWTH 39
TABLE 3 SIGNIFICANT IMPACT OF REGLATORY AUTHORITIES (IND) MAY BOOST MARKET GROWTH 40
TABLE 4 MODIFICATION OF REGULATORY PATHWAYS BY FDA MAY HAMPER THE GRWOTH OF THE MARKET 41
TABLE 5 HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2019–2023 ($MILLION) 52
TABLE 6 HUMAN MICROBIOME MARKET SIZE FOR DIABETES, BY GEOGRAPHY,
2019–2023 ($MILLION) 54
TABLE 7 HUMAN MICROBIOME MARKET SIZE FOR OBESITY, BY GEOGRAPHY,
2019–2023 ($MILLION) 55
TABLE 8 HUMAN MICROBIOME MARKET SIZE FOR AUTOIMMUNE DISORDERS,
BY GEOGRAPHY, 2019–2023 ($MILLION) 57
TABLE 9 HUMAN MICROBIOME MARKET SIZE FOR CANCER, BY GEOGRAPHY,
2019–2023 ($MILLION) 58
TABLE 10 HUMAN MICROBIOME MARKET SIZE FOR MENTAL DISORDER S,
BY GEOGRAPHY, 2019–2023 ($MILLION) 62
TABLE 11 HUMAN MICROBIOME MARKET SIZE FOR OTHER DISEASES, BY GEOGRAPHY, 2019–2023 ($MILLION) 63
TABLE 12 GLOBAL HUMAN MICROBIOME MARKET SIZE, BY APPLICATION,
2019–2023 ($MILLION) 67
TABLE 13 HUMAN MICROBIOME THERAPEUTIC APPLICATIONS MARKET SIZE,
BY GEOGRAPHY, 2019–2023 ($MILLION) 69
TABLE 14 HUMAN MICROBIOME DIAGNOSTIC APPLICATIONS MARKET SIZE,
BY GEOGRAPHY, 2019–2023 ($MILLION) 71
TABLE 15 GLOBAL HUMAN MICROBIOME MARKET SIZE, BY PRODUCT,
2019–2023 ($MILLION) 74
TABLE 16 HUMAN MICROBIOME MARKET SIZE FOR PROBIOTICS, BY GEOGRAPHY,
2019-2023 ($MILLION) 76
TABLE 17 HUMAN MICROBIOME MARKET SIZE FOR PREBIOTICS, BY GEOGRAPHY,
2019-2023 ($MILLION) 78
TABLE 18 HUMAN MICROBIOME FOODS MARKET, BY GEOGRAPHY, 2019-2023 ($MILLION) 79
TABLE 19 GLOBAL HUMAN MICROBIOME MARKET SIZE FOR MEDICAL FOODS,
BY GEOGRAPHY, 2019-2023 ($MILLION) 81
TABLE 20 GLOBAL HUMAN MICROBIOME MARKET SIZE FOR OTHER PROBIOTIC SUPPLEMENTS, BY GEOGRAPHY, 2019-2023 ($MILLION) 82
TABLE 21 GLOBAL HUMAN MICROBIOME MARKET SIZE FOR DEVICES, BY GEOGRAPHY, 2019–2023 ($MILLION) 84
TABLE 22 GLOBAL HUMAN MICROBIOME MARKET SIZE FOR DRUGS, BY GEOGRAPHY,
2019–2023 ($MILLION) 85
TABLE 23 HUMAN MICROBIOME MARKET SIZE, BY GEOGRAPHY, 2019–2023 ($MILLION) 88
TABLE 24 NORTH AMERICA: HUMAN MICROBIOME MARKET SIZE, BY APPLICATION,
2019–2023 ($MILLION) 89
TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET SIZE, BY DISEASE,
2019–2023 ($MILLION) 89
TABLE 26 NORTH AMERICA: HUMAN MICROBIOME MARKET SIZE, BY PRODUCT,
2019–2023 ($MILLION) 90
TABLE 27 EUROPE: HUMAN MICROBIOME MARKET SIZE, BY APPLICATION,
2019–2023 ($MILLION) 91
TABLE 28 EUROPE: HUMAN MICROBIOME MARKET SIZE, BY DISEASE,
2019–2023 ($MILLION) 91
TABLE 29 EUROPE: HUMAN MICROBIOME MARKET SIZE, BY PRODUCT,
2019–2023 ($MILLION) 92
TABLE 30 ASIA-PACIFIC: HUMAN MICROBIOME MARKET SIZE, BY APPLICATION,
2019–2023 ($MILLION) 93
TABLE 31 ASIA-PACIFIC: HUMAN MICROBIOME MARKET SIZE, BY DISEASE,
2019–2023 ($MILLION) 94
TABLE 32 ASIA-PACIFIC: HUMAN MICROBIOME MARKET SIZE, BY PRODUCT,
2019–2023 ($MILLION) 94
TABLE 33 ROW: HUMAN MICROBIOME MARKET SIZE, BY APPLICATION,
2019–2023 ($MILLION) 95
TABLE 34 ROW: HUMAN MICROBIOME MARKET SIZE, BY DISEASE, 2019–2023 ($MILLION) 95
TABLE 35 ROW: HUMAN MICROBIOME MARKET SIZE, BY PRODUCT, 2019–2023 ($MILLION) 96
TABLE 36 NEW PRODUCT LAUNCHES, 2011–2014 99
TABLE 37 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS, 2011–2014 99
TABLE 38 EXPANSIONS, 2011–2014 102
TABLE 39 CLINICAL /RESEARCH STUDIES, 2011–2014 102
TABLE 40 CLINICAL /RESEARCH STUDIES, 2011–2014 103
TABLE 41 OTHER DEVELOPMENTS, 2011–2014 105

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 18
FIGURE 2 BOTTOM-UP APPROACH 19
FIGURE 3 TOP-DOWN APPROACH 19
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY DEMAND & SUPPLY SIDE 20
FIGURE 5 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY/INSTITUTE, DESIGNATION, & REGION 20
FIGURE 6 HUMAN MICROBIOME PRODUCT MARKET SNAPSHOT (2019 VS. 2023): THE PROBIOTICS MARKET IS EXPECTED TO DOUBLE BY 2023 FROM 2019 24
FIGURE 7 HUMAN MICROBIOME MARKET, BY PRODUCT, 2019 25
FIGURE 8 GLOBAL HUMAN MICROBIOME MARKET SHARE, 2019 26
FIGURE 9 ATTRACTIVE MARKET OPPORTUNITIES IN HUMAN MICROBIOME 27
FIGURE 10 PREBIOTICS TO CAPTURE THE LION’S SHARE GLOBALLY 28
FIGURE 11 NORTH AMERIA WILL BE THE FASTEST GROWING MARKET IN THE FORECAST PERIOD 29
FIGURE 12 ACUTE DIARRHEA WILL CAPTURE MAXIMUM MARKET SHARE 29
FIGURE 13 PREBIOTIC WILL GROW AT THE HIGHEST RATE POST THE LAUNCH OF MICROBIOME PRODUCTS 30
FIGURE 14 NORTH AMERICAN MARKET SOON TO ENTER EXPONENTIAL GROWTH PHASE IN COMING YEARS 30
FIGURE 15 THERAPEUTICS WILL CAPTURE MAXIMUM MARKET SHARE IN NEXT SEVEN YEARS 31
FIGURE 16 HUMAN MICROBIOME MARKET SEGMENTATION, BY APPLICATION 33
FIGURE 17 HUMAN MICROBIOME MARKET SEGMENTATION: BY DISEASE 34
FIGURE 18 HUMAN MICROBIOME MARKET SEGMENTATION: BY PRODUCT 34
FIGURE 19 HUMAN MICROBIOME AS A NEW VALIDATED TARGET FOR DRUG DEVELOPMENT MAY SPUR THE MARKET 36
FIGURE 20 FUNDS PROVIDED FOR MICROBIOME RESEARCH BY VARIOUS MEDICAL RESEARCH AGENCIES 42
FIGURE 21 EMERGING OPPORTUNITIES IN THE HUMAN MICROBIOME MARKET RESULTING IN THE ACQUISITION OF SMALL PLAYERS BY MAJOR FIRMS 43
FIGURE 22 PORTER’S FIVE FORCES ANALYSIS (2019): AVAILABLE OPPORTUNITIES DUE TO THE EMERGING MARKET WILL LEAD TO INCREASED COMPETITION 44
FIGURE 23 STRATEGIC BENCHMARKING: KEY PLAYERS LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR RESEARCH AND TECHNOLOGY INTEGRATION & PRODUCT DEVELOPMENT 48
FIGURE 24 STRATEGIC BENCHMARKING: SPOTLIGHT FALLS ON VITHERA PHARMACEUTICALS IN THE CHRONIC LIFESTYLE DISEASES MARKET WITH ITS BIG STRATEGIC MOVES 49
FIGURE 25 ACUTE DIARRHEA IS THE LARGEST DISEASE SEGMENT IN THE MARKET 52
FIGURE 26 HIGH PREVALENCE OF DIABETES IN EUROPE FUELING GROWTH OF HUMAN MICROBIOME DISEASE MARKET 53
FIGURE 27 HUMAN MICROBIOME OBESITY MARKET IS EXPECTED TO HIGHEST GROWTH IN NORTH AMERICA 55
FIGURE 28 AUTOIMMUNE DISORDERS MARKET TO WITNESS HIGHEST GROWTH IN NORTH AMERICA 56
FIGURE 29 HUGE INVESTMENTS FOR CANCER RESEARCH GLOBALLY EXPECTED TO DRIVE THE HUMAN MICROBIOME MARKET FOR CANCER 58
FIGURE 30 INCREASING PREVALENCE OF ACUTE DIARRHEAL INFECTIONS WILL LEAD TO GROWTH OF HUMAN MICROBIOME MARKET 59
FIGURE 31 HUMAN MICROBIOME MARKET SIZE FOR ACUTE DIARRHEA, BY GEOGRAPHY, 2019–2023 ($MILLION) 60
FIGURE 32 HUMAN MICROBIOME MARKET FOR MENTAL DISORDERS EXPECTED TO SHOW MODERATE GROWTH WITH EUROPE DOMINATING THE MARKET 62
FIGURE 33 THE MARKET IS EXPECTED TO SHOW POTENTIAL GROWTH IN NORTH AMERICA 63
FIGURE 34 THERAPEUTIC SEGMENT SET TO OUTPACE THE HUMAN MICROBIOME APPLICATIONS MARKET 66
FIGURE 35 THERAPEUTICS IS THE FASTEST-GROWING SEGMENT IN THE GLOBAL HUMAN MICROBIOME APPLICATIONS MARKET 67
FIGURE 36 INCREASING PREVALENCE OF CHRONIC LIFESTYLE DISEASES IN EUROPE TO PROPEL THE GROWTH OF THERAPEUTIC SEGMENT 69
FIGURE 37 EUROPE EXPECTED TO DOMINATE THE DIAGNOSTIC SEGMENTS 2021 ONWARDS 70
FIGURE 38 PROBIOTICS IS EXPECTED TO DOMINATE THE HUMAN MICROBIOME MARKET 74
FIGURE 39 AWARENESS AMONG POPULATION & SAFETY OF PROBIOTICS IS EXPECTED TO FUEL THE GROWTH OF PROBIOTIC MARKET 76
FIGURE 40 PREBIOTICS IN NORTH AMERICA IS EXPECTED TO GROW AT A HIGH RATE DUE TO DEVELOPMENT AND ITS USE FOR TREATMENT OF VARIOUS INDICATIONS 77
FIGURE 41 NORTH AMERICA EXPECTED TO DOMINATE THE HUMAN MICROBIOME FOODS MARKET 79
FIGURE 42 EUROPE IS EXPECTED TO DOMINATE THE HUMAN MICROBIOME MEDICAL FOOD MARKET 80
FIGURE 43 NORTH AMERICAN MARKET FOR OTHER PROBIOTIC SUPPLEMENTS WILL DOUBLE IN FIVE YEARS 82
FIGURE 44 DEVICES SEGMENT IS EXPECTED TO GAIN PACE IN THE MARKET FROM 2021 ONWARDS, WITH EUROPE DOMINATING 83
FIGURE 45 INORGANIC GROWTH STRATEGIES BETWEEN COMPANIES WILL INCREASE THE DEMAND FOR MICROBIOME-BASED DRUGS IN EUROPE 85
FIGURE 46 GLOBAL HUMAN MICROBIOME MARKET: GEOGRAPHIC SNAPSHOT (2019) 87
FIGURE 47 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS AND COLLABORATIONS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 97
FIGURE 48 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES WAS THE KEY STRATEGY 98
FIGURE 49 GEOGRAPHIC REVENUE MIX OF TOP MARKET PLAYERS 107

【レポートのキーワード】

ヒトマイクロバイオーム、微生物、治療、診断、病、プロバイオティクス、プレバイオティクス、食品、医療食、デバイス、薬